The first sequences twill be deployed to the 3 clinical sites. The details of the sequence development will be influenced by results from simulations (WP1) and TFM data (WP6) providing targets for data quality and SNR. The following years are dedicated to sequence optimization and improved 3D strain acquisition

WP4 collects initially ground truth data for IFP for validation of the reconstruction method (WP1). Subsequently, MRF derived parameters will be studied to verify their usefulness in predicting the metastatic spread in a preclinical breast/liver/brain cancer model

WP7 is the only therapeutic WP where active processes of mechanotransduction are studied. It represents a truly exploratory workpackage that, within the consortium, uniquely leverages outcomes to examine an entirely new modality for signalling and treatment in cancer

WP8 Microvascular involvement and Response to Therapy for HCCs predicted by MRF

WP8, WP9, and WP10 are the clinical WPs for liver, brain, and breast. Clinical protocols will be developed, MRF hardware installed and sequences tested. All sites will then start with MRF data collection during the 1st phase of clinical testing. Later, newly developed sequence, protocols, and potential hardware changes will be introduced.